Trademark: ALLAKOS 2275626
Word
ALLAKOS
ID
2275626
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
25 February 2022
Registration Date
25 February 2022
Renewal Date
25 February 2032
Owner(s)
Service
Goods and Services:
Class 5:
Pharmaceutical and therapeutic preparations for the treatment of gastrointestinal, skin, multi-organ, respiratory, ophthalmic, autoimmune, cardiovascular, central nervous system, endocrine, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, urogenital, urological, and/or viral diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic esophagitis, ulcerative colitis, crohn's disease, irritable bowel syndrome, functional gastrointestinal disease, chronic urticaria, atopic dermatitis, indolent systemic mastocytosis, mast cell activation syndrome, idiopathic pulmonary fibrosis, eosinophilic asthma, asthma, conjunctivitis, vitiligo, and viral infections.
Pharmaceutical and therapeutic preparations for the treatment of gastrointestinal, skin, multi-organ, respiratory, ophthalmic, autoimmune, cardiovascular, central nervous system, endocrine, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, psychiatric, urogenital, urological, and/or viral diseases and disorders; pharmaceutical and therapeutic preparations for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic esophagitis, ulcerative colitis, crohn's disease, irritable bowel syndrome, functional gastrointestinal disease, chronic urticaria, atopic dermatitis, indolent systemic mastocytosis, mast cell activation syndrome, idiopathic pulmonary fibrosis, eosinophilic asthma, asthma, conjunctivitis, vitiligo, and viral infections.